Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RDHL | 424B5 | bearish | 6/10 | RedHill Biopharma filed a 424B5 prospectus supplement to increase the maximum aggregate offering amount of ADSs availabl | Oct 13, 2026 |
| SLN | SC 13G | neutral | 3/10 | Tetragon Financial Group Limited and its affiliates disclosed a 5.2% passive stake in Silence Therapeutics plc via a new | Oct 13, 2026 |
| MTVA | 3 | neutral | 2/10 | Sarah Kaplan Browne filed a Form 3 initial statement of beneficial ownership with the SEC, reporting her position as Chi | Oct 13, 2026 |
| GNTA | 6-K | bearish | 5/10 | Genenta Science S.p.A. reported that its Extraordinary Shareholders' Meeting failed to approve a proposed name change to | Oct 13, 2026 |
| AGMB | PRESS-RELEASE | bullish | 6/10 | Agomab Therapeutics dosed the first patient in its Phase 2b NOV-ERA trial of ontunisertib for Fibrostenosing Crohn's dis | Oct 13, 2026 |
| SNTI | DEFA14A | mixed | 6/10 | Senti Biosciences adjourned its 2026 Annual Meeting on October 8 without conducting business, despite a quorum being pre | Oct 13, 2026 |
| SNTI | 8-K | bearish | 5/10 | Senti Biosciences adjourned its 2026 Annual Meeting of Stockholders without conducting any business, despite a quorum be | Oct 13, 2026 |
| AVBP | SC 13G | neutral | 3/10 | Vivo Opportunity Fund Holdings, L.P. and affiliated entities filed a new Schedule 13G disclosing a 5.0% aggregate benefi | Oct 13, 2026 |
| LBRX | SC 13G/A | neutral | 2/10 | JPMorgan Chase & Co. filed an amended Schedule 13G disclosing beneficial ownership of 1,401,790 shares of LB Pharmaceuti | Oct 13, 2026 |
| LXEO | SC 13G | neutral | 3/10 | JPMorgan Chase & Co. disclosed a 5.5% passive stake in Lexeo Therapeutics via a Schedule 13G filed October 13, 2026, hol | Oct 13, 2026 |
| RGNX | SC 13G | neutral | 3/10 | JPMorgan Chase disclosed a 5.3% passive stake in REGENXBIO Inc. via a new SC 13G filing, confirming passive intent. This | Oct 13, 2026 |
| RYTM | SC 13G | neutral | 3/10 | JPMorgan Chase & Co. disclosed a passive 5.1% stake in Rhythm Pharmaceuticals via a new Schedule 13G filing, representin | Oct 13, 2026 |
| MANE | SC 13G | neutral | 4/10 | JPMorgan Chase & Co. filed a Schedule 13G disclosing a 5.6% passive stake in Veradermics, Inc. as of September 30, 2026. | Oct 13, 2026 |
| BIOF | 144 | neutral | 2/10 | Director Chris J. Kneppers filed a Form 144 notice of intent to sell 908,355 shares of Blue Biofuels, Inc. common stock, | Oct 13, 2026 |
| CRLBF | 6-K | neutral | 2/10 | Cresco Labs filed a supplement to its management information circular clarifying voting rights and minority approval pro | Oct 13, 2026 |
| LTRN | SC 13G/A | neutral | 3/10 | Empery Asset Management filed an amended Schedule 13G disclosing a passive 4.99% beneficial ownership stake in Lantern P | Oct 13, 2026 |
| CLNN | SC 13G/A | neutral | 3/10 | Empery Asset Management, LP filed an amendment to its Schedule 13G, reporting a passive stake of 1.56% in Clene Inc. as | Oct 13, 2026 |
| OTLK | SC 13G | neutral | 4/10 | Empery Asset Management, LP filed a Schedule 13G disclosing a passive 8.73% stake in Outlook Therapeutics, Inc., represe | Oct 13, 2026 |
| MRK | 8-K | neutral | 2/10 | Merck announced the election of Paul J. Diaz to its Board of Directors, effective November 1, 2026. Mr. Diaz, a managing | Oct 13, 2026 |
| GSK | 6-K | neutral | 2/10 | GSK filed a Form 6-K disclosing routine dividend reinvestment transactions by multiple PDMRs (including the CEO, Preside | Oct 13, 2026 |
| TCRT | PRESS-RELEASE | bullish | 8/10 | Alaunos Therapeutics completed the acquisition of Velaris Therapeutics in a reverse merger, concurrently raising $350 mi | Oct 13, 2026 |
| APUS | PRESS-RELEASE | neutral | 3/10 | MindWave Innovations, a subsidiary of APUS, announced that its NILA token will be listed on the Pionex exchange starting | Oct 13, 2026 |
| TCRT | 8-K | bullish | 8/10 | Alaunos Therapeutics (TCRT) has entered into a definitive merger agreement to acquire Velaris Therapeutics in a reverse | Oct 13, 2026 |
| BIAF | 8-K | neutral | 3/10 | bioAffinity Technologies filed an 8-K announcing a poster presentation at CHEST 2026 on its investigational sputum-based | Oct 13, 2026 |
| APUS | 8-K | neutral | 4/10 | Apimeds Pharmaceuticals US, Inc. (APUS) announced via its wholly owned subsidiary MindWave Innovations Inc. that it has | Oct 13, 2026 |
| OTLC | 8-K | neutral | 2/10 | Oncotelic Therapeutics filed an 8-K to report presentations at Drug Discovery 2026 regarding its PDAOAI platform and hep | Oct 13, 2026 |
| PHIO | 8-K | neutral | 3/10 | Phio Pharmaceuticals announced the successful completion of its first commercial-scale cGMP batch of PH-762 drug substan | Oct 13, 2026 |
| NRSN | 6-K | mixed | 6/10 | NeuroSense announced its Nasdaq hearing is scheduled for November 10, 2026, following a delisting determination for fail | Oct 13, 2026 |
| INKT | 144 | neutral | 2/10 | Jennifer Buell, President and CEO of MiNK Therapeutics, filed a Form 144 notice to sell 6,938 shares of common stock, va | Oct 13, 2026 |
| CRVO | 8-K | bullish | 6/10 | CervoMed reported initial 12-week biomarker data from its Phase 2a trial of neflamapimod in nfvPPA, showing a mean reduc | Oct 13, 2026 |